3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
22
Unknown
3
Recruiting
2
Active not recruiting
2
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
10
Esophageal Neoplasms
4
Neoplasms
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Oesophago-gastric Cancer
1
KRAS and NRAS Wild-type Colorectal Cancer
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Cone Dystrophy 3
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Breast Neoplasms
1
Advanced Colorectal Cancer
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Fluorouracil
25
Oxaliplatin
24
Irinotecan
24
Leucovorin
23
Bevacizumab
23
Capecitabine
18
Cetuximab
15
Radiotherapy
6
Gene Expression Profiling
5
regorafenib
4
Immunohistochemistry
4
Gemcitabine
4
Folfox protocol
4
Colonoscopy
4
Cisplatin
4
Celecoxib
4
Amplified Fragment Length Polymorphism Analysis
4
Reverse Transcriptase Polymerase Chain Reaction
3
Receptor Protein-Tyrosine Kinases
3
Polymerase Chain Reaction
3
Nivolumab
3
Mitomycin
3
Doxorubicin
3
Cyclophosphamide
3
Cholecalciferol
3
Biopsy
3
Aspirin
3
sargramostim
2
pembrolizumab
2
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Colonic Neoplasms
×
Panitumumab
×
Clear all
NCT02015923
2021-03-16
CCRe-IV
Hospital Universitari de Bellvitge
Phase 4
Terminated
107 enrolled